Empagliflozin add on to insulin premix effectively lowers blood sugar in diabetes: Study
Taiwan: The addition of SGLT2 inhibitor empagliflozin versus linagliptin for 24 weeks to premixed insulin provides better blood sugar control in Asian patients with poorly controlled type 2 diabetes (T2D), suggest a recent study in the journal Diabetes & Metabolism. Further, empagliflozin addition also provided greater reductions in systolic blood pressure and body weight.
Diabetes is a chronic, metabolic disease characterized by increased levels of blood sugar and involves s β-cell dysfunction, and β-cell failure requires insulin for achieving optimal blood sugar control. Premixed insulin and basal insulin play important roles in poorly controlled T2D. In case, prandial blood sugar levels are not controlled adequately by basal insulin, basal/prandial regimens or premixed insulin can be used for further lowering glycated hemoglobin (HbA1c). Still, many diabetes patients are unable to achieve the recommended HbA1c targets despite an intensified treatment regimen. Also, a number of concerns limit the use of higher insulin doses for maintaining blood sugar control. Concerns include weight gain and hypoglycemia. Therefore, oral antidiabetic drugs (OADs) are required to mitigate the weight gain and risk of hypoglycemia associated with intensive insulin therapy.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.